首页 | 本学科首页   官方微博 | 高级检索  
检索        


Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light‐Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment
Authors:Riccardo Caccialanza MD  Giovanni Palladini MD  PhD  Catherine Klersy MD  MSc  Emanuele Cereda MD  PhD  Chiara Bonardi RD  Barbara Cameletti RD  Lara Quarleri RD  Elisabetta Montagna RD  Andrea Foli MD  Paolo Milani MD  Francesca Lavatelli MD  Carlo Marena MD  Giampaolo Merlini MD  PhD
Institution:1. Nutrition and Dietetics Service, Fondazione IRCCS Policlinico, San Matteo, Italy;2. Amyloidosis Research and Treatment Center, Biotechnology Research Laboratories, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy;3. Biometry and Clinical Epidemiology Service, Fondazione IRCCS Policlinico, San Matteo, Italy;4. Medical Direction, Fondazione IRCCS Policlinico, San Matteo, Italy
Abstract:Background: Nutrition status was shown to be a prognostic factor in patients with immunoglobulin light‐chain amyloidosis (AL). However, malnutrition was associated with cardiac involvement, thus suggesting potential interactions. This study aim was to clarify the association among nutrition status, cardiac stage, and mortality in AL. Methods: One hundred twenty‐eight consecutive newly diagnosed, treatment‐naïve patients with histologically confirmed AL were enrolled. Anthropometric, biochemical, and clinical variables were assessed. Results: At multivariable Cox proportional hazard analysis, body mass index (BMI) < 22 kg/m2 (HR = 1.98, 95% CI = 1.09–3.56) and unintentional 6‐month weight loss (WL) ≥ 10% (HR = 1.94, 95% CI = 1.00–3.74) resulted in independent predictors of survival after controlling for hematologic response to treatment (HR = 0.27, 95% CI = 0.14–0.53) and cardiac stage (Mayo Clinic stage III, HR = 4.42, 95% CI = 2.61–7.51). There was no effect modification of malnutrition on mortality by cardiac stage (P for interaction = .27). Moderate and severe malnutrition (prevalence: 21.9% and 7.8%, respectively) similarly increased the risk of death (HR = 3.09, 95% CI = 1.75–5.46; 2.88, 95% CI = 1.23–6.72, respectively). Conclusions: In AL, malnutrition at diagnosis is a frequent comorbidity that affects the prognosis independently of hematologic response to treatment and cardiac stage. Nutrition status should be systematically considered in future intervention trials in AL. Nutrition support trials are warranted.
Keywords:AL  amyloidosis  malnutrition  cardiac stage  treatment response  survival
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号